Company news

Apollomics Inc. news in 2024

Apollomics Inc.'s news releases, calls and decks from 2024, newest first.

View company

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

December 19, 2024

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

December 11, 2024

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

December 9, 2024

Apollomics Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

November 22, 2024

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

November 20, 2024

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

September 15, 2024

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

August 13, 2024

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

August 12, 2024

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

July 15, 2024

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

July 2, 2024

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

June 3, 2024

Apollomics Announces Presentation at the 2024 BIO International Convention

May 28, 2024

Apollomics Announces Private Placement Financing and Addition to Board of Directors

May 7, 2024

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

April 24, 2024

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

April 9, 2024

Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

April 1, 2024

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

March 27, 2024

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

March 25, 2024

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

March 3, 2024

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

January 2, 2024

Calls in 2024